Abstract
The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.
Keywords: Late sodium current, cardiac sodium channel, arrhythmias.
Current Pharmaceutical Design
Title:An Emerging Antiarrhythmic Target: Late Sodium Current
Volume: 21 Issue: 8
Author(s): T. Banyasz, N. Szentandrassy, J. Magyar, Z. Szabo, P.P. Nanasi, Y. Chen-Izu and L.T. Izu
Affiliation:
Keywords: Late sodium current, cardiac sodium channel, arrhythmias.
Abstract: The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has emerged as a potentially major arrhythmogenic mechanism in various heart diseases, attracting the attention of clinicians and researchers. Research activity on INa,L has exponentially increased since Ranolazine, an FDA-approved antianginal drug was shown to successfully suppress cardiac arrhythmias by inhibiting INa,L. This review aims to summarize and discuss a series of papers focusing on the cardiac late sodium current and its regulation under physiological and pathological conditions. We will discuss critical evidences implicating INa,L as a potential target for treating myocardial dysfunction and cardiac arrhythmias.
Export Options
About this article
Cite this article as:
Banyasz T., Szentandrassy N., Magyar J., Szabo Z., Nanasi P.P., Chen-Izu Y. and Izu L.T., An Emerging Antiarrhythmic Target: Late Sodium Current, Current Pharmaceutical Design 2015; 21 (8) . https://dx.doi.org/10.2174/1381612820666141029111729
DOI https://dx.doi.org/10.2174/1381612820666141029111729 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Editorial (Thematic Issue: Angiogenesis in the Development of Cardiovascular Diseases)
Current Angiogenesis (Discontinued) Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Controversial Issues of Abortion License According to Religious and Jurisprudential Laws in Iran: A Systematic Review
Current Women`s Health Reviews New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design Preface (Hot Topic: Endocrine , Metabolic and Immunological Agents Executive Editors : Allan S . Wagman / Wayne L . Cody)
Current Pharmaceutical Design Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction
Current Hypertension Reviews Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets Marine Products with Anti-Protozoal Activity: A Review
Current Clinical Pharmacology Editorial: Paving the Way for Improved Antiplatelet Therapy
Current Pharmaceutical Design